NEW YORK, NY / ACCESSWIRE / August 1, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
IonQ, Inc. (NYSE:IONQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ionq-inc-loss-submission-form?prid=30453&wire=1
Lead Plaintiff Deadline: August 1, 2022
Class Period: March 30, 2021 - May 2, 2022
Allegations against IONQ include that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company's 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ's quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ's revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.
Unilever PLC (NYSE:UL)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/unilever-plc-loss-submission-form?prid=30453&wire=1
Lead Plaintiff Deadline: August 15, 2022
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Allegations against UL include that: a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in 'Occupied Palestinian Territory' ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.
TG Therapeutics, Inc. (NASDAQ:TGTX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tgtx-lawsuit-loss-submission-form?prid=30453&wire=1
Lead Plaintiff Deadline: September 16, 2022
Class Period: January 15, 2020 - May 31, 2022
Allegations against TGTX include that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: